Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Potential coverage of a multivalent M protein-based group A streptococcal vaccine.
[acute rheumatic fever]
The
greatest
burden
of
group
A
streptococcal
(
GAS
)
disease
worldwide
is
due
to
acute
rheumatic
fever
(
ARF
)
and
rheumatic
heart
disease
(
RHD
)
.
Safe
,
effective
and
affordable
vaccines
designed
to
prevent
GAS
infections
that
trigger
ARF
could
reduce
the
overall
global
morbidity
and
mortality
from
RHD
.
The
current
study
evaluated
the
potential
coverage
of
a
new
30
-
valent
M
protein-based
vaccine
using
GAS
isolates
from
school
children
in
Bamako
,
Mali
,
a
population
at
high
risk
for
the
development
of
RHD
.
T
he
bactericidal
activity
of
rabbit
antisera
against
the
30
-
valent
vaccine
was
assessed
using
a
collection
of
GAS
isolates
recovered
during
a
study
of
the
epidemiology
of
pharyngitis
in
Bamako
.
Single
isolates
representing
42
of
67
emm-types
,
accounting
for
85
%
of
the
GAS
infections
during
the
study
,
were
evaluated
.
All
(
14
/
14
)
of
the
vaccine
emm-types
in
the
collection
were
opsonized
(
bactericidal
killing
>
50
%
)
and
26
/
28
non-vaccine
types
were
opsonized
.
Bactericidal
activity
was
observed
against
60
%
of
the
total
emm-types
recovered
in
Bamako
,
which
accounted
for
81
%
of
all
infections
.
Multivalent
vaccines
comprised
of
N-
terminal
M
peptides
elicit
bactericidal
antibodies
against
a
broad
range
of
GAS
serotypes
,
indicating
that
their
efficacy
may
extend
beyond
the
emm-types
included
in
the
vaccine
.
